
Opinion|Videos|May 21, 2025
Ideal Candidates for Bronchiectasis Surgeries
Panelists discuss how ideal candidates for bronchiectasis surgery have localized disease on CT scan and bronchoscopy, adequate pulmonary function (orced expiratory volume in 1 second > 40%), and whose infections are controlled prior to surgery.
Advertisement
Episodes in this series

Clinical Brief: Surgical Management of Bronchiectasis
Main Discussion Topics
- Ideal surgical candidates have localized disease and adequate pulmonary function.
- Preoperative optimization of infection status is crucial for successful outcomes.
- Collaboration between pulmonologists and surgeons is essential during patient selection.
Key Points for Physicians
- Surgical consideration criteria:
- Forced expiratory volume in 1 second and diffusing capacity of the lung for carbon monoxide values of greater than 40% to minimize morbidity and mortality
- Disease localized to a segment or lobe on CT imaging
- Identification of affected area via bronchoscopy
- Adequate control of active infection before surgery
- Common indications include:
- Refractory infections despite optimal medical management
- Intolerance to long-term antibiotics
- Aspergillus fungal masses
- Macrolide-resistant nontuberculous mycobacteria with localized infection
- Hemoptysis (after initial management with bronchoscopy/embolization)
Notable Insights
Complete resection of affected areas can lead to significant symptom improvement and reduced need for ongoing medications when disease is localized.
Clinical Significance
Surgical management represents an important option for select patients with bronchiectasis with localized disease when medical management has failed to control symptoms or infections.
Advertisement
Related to this article

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.

Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.

Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.

The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
2
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
3
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
4
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
5

